The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
@sagetrade
Why listen to anyone, if you think it's ribena being touted sell up and leave everyone to their own decisions. We've all been here a very long time and your opinions are wasted.
You really have a hard on for the 3 muscrats, have they
been sorting your missus or something?
They have been screening fortnightly patients since 13/12/23 42 days. 127 days last mention of cohort 7. I am assuming 3+3+3 + 6 observation 105 days .
I really would expect, as said before an RNS on end of 7 or start of fortnightly
@JT I would like to hear either completion of cohort 7 or start of the fortnightly dosing as presently we are left very much wondering what is happening (I know they are getting on with it ) and as we all know we have been told we are at the start of the value curve. Oh and one other thing, funding yes I know AS says not to worry but it does cross my mind.
Touk knows it all, whether it's right or wrong he knows it. Or is it thorn who knows ? I suppose we will never know who knows oh apart from Sujood who knows everyone who knows everything but don't forget Hurst bot who also knows.
You are in the room
I have been having a quick glance through all the approved ADC's and there is still a severe problem with side effects then the costs are quite astronomical in some cases. The improvent on PFS is not all that great and AVA 6K has surpassed the best already with no MTD which the ADC's still have.
Anyway enough for the day and thanks JT for stopping me being lazy.
JT Thanks for that but there are now 15
Table of Contents
Structural characteristics of ADCs
Antibody-drug conjugates – mechanism of action
Approved ADCs
Mylotarg
Adcetris
Kadcyla
Besponsa
Lumoxiti
Polivy
Padcev
Enhertu
Trodelvy
Blenrep
Zynlota
Tivdak
Elahere
The 1st mylotarg £10k for 1 injection and the list of serious side effects is endless.